Autologous stem cell transplantation in first-line treatment of high-risk aggressive non-Hodgkin's lymphoma.

Abstract

A single center, retrospective analysis evaluating the outcome of patients with poor-risk aggressive non-Hodgkin's lymphoma (NHL) treated with high-dose chemotherapy and autologous stem cell transplantation (ASCT) as a part of firstline therapy. Forty-seven patients younger than 65 years with diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), peripheral T-cell lymphoma (PTCL) or alk-negative anaplastic large cell lymphoma (ALCL) underwent ASCT between July 1997 and November 2005. Patients with DLBCL and alk-negative ALCL had 2 or 3 age-adjusted International Prognostic Index risk factors. All patients were transplanted after MACOP-B induction therapy followed by 2 courses of DHAP and myeloablative chemotherapy BEM or CBV. The complete response rate to the high-dose therapy was 79% with an estimated 5-year progression-free survival of 66%. At a median follow-up of 35 months (range, 16 to 112 months) the estimated overall survival at five years was 59%. There were 4 treatment-related deaths. Twenty-nine of 47 patients remain in complete remission. Our results confirm the efficacy of high-dose therapy with ASCT during first-line treatment of patients with poor-prognosis aggressive lymphoma, with substantial number of patients cured by using this treatment approach.

• Authors: A Vranovsky, M Ladicka, J Lakota
• Journal: Neoplasma (Neoplasma) Vol. 55 Issue 2 Pg. 107-12 ( 2008) ISSN: 0028-2685 [Print] Slovakia
• PMID: 18652043 (Publication Type: Journal Article)

Chemical References

• Cytarabine
• Bleomycin
• Vincristine
• Dexamethasone
• Doxorubicin
• Cyclophosphamide
• Prednisolone
• Cisplatin
• Methotrexate

Topics

• Adult
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Bleomycin (therapeutic use)
• Cisplatin (therapeutic use)
• Combined Modality Therapy
• Cyclophosphamide (therapeutic use)
• Cytarabine (therapeutic use)
• Dexamethasone (therapeutic use)
• Doxorubicin (therapeutic use)
• Female
• Hematopoietic Stem Cell Transplantation (adverse effects)
• Humans
• Lymphoma, Non-Hodgkin (mortality, therapy)
• Male
• Methotrexate (therapeutic use)
• Middle Aged
• Prednisolone (therapeutic use)
• Retrospective Studies
• Transplantation, Autologous
• Vincristine (therapeutic use)